info@flamel.com
Home | Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
2008
2007
2006
2005
2004
2003
2002
2001
Archives


Latest News

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet


Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here

"Novel Sustained Release Formulation of IL-2 Improves Pharmacokinetics Performance
and Demonstrates Potent Activation of Immunological Cell Line" click here

Micropump® Technologies
From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info
December 20, 2007
Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
Merck Serono press release

October 30, 2007
Flamel Technologies Announces Third Quarter Results; Further Medusa Portfolio Expansion; and Stronger Coreg Revenues

October 25, 2007
Flamel Technologies Announces Positive Top Line Results of a Clinical Trial of IFN-alpha-XL versus PegIntron™ in Patients with Chronic Hepatitis C Virus Infection

October 18, 2007
Flamel Technologies Announces Positive Results of a Phase I Trial of FT-105 Basal Insulin versus Lantus®

September 12, 2007
Flamel Technologies Announces Medusa® License Agreement with Wyeth Pharmaceuticals

August 2, 2007
Flamel Technologies 2007 2nd Quarter Results Webcast
Conference call replay will be available through August 16, 2007.
To access the replay, please dial 800-642-1687 or 706-645-9291. The Conference ID number is 11213762

August 1, 2007
Flamel Technologies Announces Second Quarter Results, New Medusa Relationships, and Ongoing Work on COREG CR®

July 26, 2007
Flamel Technologies Announces Announces Projected Release Date of Second Quarter Results, Conference Call

May 15, 2007
Flamel Technologies Announces Results of Annual Meeting

May 07, 2007
Flamel Technologies Announces First Quarter Results;
COREG CR™ Launch; and Strong Sales of Product to GSK

April 30, 2007
Flamel Technologies Announces Projected Release Date of First Quarter Results, Conference Call

March 23, 2007
Flamel Technologies Welcomes Nationwide Availability of COREG CR™

March 07, 2007
Flamel Technologies Announces Fourth Quarter and Full Year 2006 Results and Conference Call

March 01, 2007
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Full Year 2006 Results and Conference Call

Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2007 Flamel Technologies S.A. All rights reserved